Gapping up
In reaction to earnings/guidance:
- WING +7.1% (Q1 domestic same-store sales increased +20.7%), GES +6.8%, MU +4.7%, VISL +3.1%, BOLT +2.6%, SPWH +1.2%
Other news:
- FTFT +28.7% (acquires bitcoin mining farm Nanjing Ribensi for approx. $9.1 mln)
- QS +14.2% (meets technical milestone to close additional $100 mln investment by Volkswagen)
- FBIO +7.6% (partner Journey Medical enters into a definitive agreement with Dermira to acquire QBREXZA)
- THBR +7.5% (indicated higher pre-market after indie Semiconductor CEO discussed deal, business prospects on CNBC's Mad Money)
- NIO +5.8% (reports March deliveries incraesed 373% yr/yr)
- FUBO +5.6% (announces carriage agreement with Marquee Sports Network)
- XPEV +5.5% (reports March deliveries increased 384% yr/yr)
- CAMT +5.3% (receives orders of over $20 mln for advanced packaging and compound semiconductors applications)
- OCDX +4.9% (to accelerate COVID-19 antigen and antibody test development through new contract with BARDA and the Department of Defense)
- EQOS +4.4% (Diginex's EQUOS has expanded its stablecoin offering by listing Tether, providing an onramp into the EQUOS ecosystem for traders who use USDT as a base currency)
- VLDR +3.7% (announced a multi-year agreement with AGM Systems)
- STRL +3.4% (awarded $10.5 mln contract by City of Phoenix)
- DDOG +3% (extends Network Performance Monitoring to Windows)
- ALT +2.6% ( reports clinical data on its NasoShield intranasal anthrax vaccine candidate)
- NH +2.5% (files for $200 mln mixed securities shelf offering)
- AONE +2.4% (appoints Mark Schwartz as Chief Financial Officer)
- CPB +2.2% (to sell Plum Organics to Sun-Maid Growers of California)
- QDEL +2.2% (received Emergency Use Authorization for QuickVue At-Home OTC COVID-19 Test)
- TSM +2.2% (entering a period of higher growth as the multiyear megatrends of 5G and HPC are expected to fuel strong demand for semiconductor technologies in the next several years)
- NVTA +2.1% (increases genetic testing for patients who are at risk of neurodegenerative conditions)
- LLNW +2% (names new non-executive Chairman)
- LPTX +1.6% (completes enrollment for the first-line patient cohort in the DisTinGuish study, a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01)
- CWH +1.4% (to acquire multi-location Hilltop RV Superstore)
- BNTX +1.4% (Pfizer and BioNTech (BNTX) updated topline results for their COVID vaccine Phase 3 study; was 91.3% effective against COVID through up to six months after second dose)
Analyst comments:
- QURE +7% (upgraded to Buy from Neutral at Mizuho)
- BILI +4.7% (initiated with a Buy at Goldman)
- VSAT +4% (upgraded to Strong Buy from Outperform at Raymond James)
- AYI +3% (upgraded to Outperform from Neutral at Robert W. Baird)